First FDA-Approved Treatment for Myelofibrosis, JakafiTM (ruxolitinib), Discussed in Multiple Presentations at 2011 ASH Annual Meeting
Click here to view press release
FDA Approves Incyte's JakafiTM (ruxolitinib) for Patients with Myelofibrosis
Click here to view press release
JakafiTM (ruxolitinib) Prescribing Information
Click here to view insert
JakafiTM Website
Click here for website
Incyte Reports Third Quarter 2011 Financial Results and Provides Update on Key Clinical Programs
Click here to view press release
